LOS ANGELES, United States: The report is a brilliant presentation of critical dynamics, regional growth, competition, and other important aspects of the global Testosterone Replacement Therapy market. It provides in depth market scenario includes current market size estimates, market splits by vendors, end user segments and by regions. Each regional market studied in the report is carefully analyzed to explore key opportunities and business prospects they are expected to offer in the near future. The authors of the report profile some of the leading names of the global Testosterone Replacement Therapy market on the basis of various factors. This equips players with crucial information and data to improve their business tactics and ensure a strong foothold in the global Testosterone Replacement Therapy market.

The research study is a good resource to have for becoming aware of the latest developments and future advancements in the global Testosterone Replacement Therapy market. The authors of the report used industry-best primary and secondary research methodologies and tools for collecting, verifying, and re-validating data and information related to the global Testosterone Replacement Therapy market. Global, regional, segment, and other market figures, such as revenue, volume, CAGR, and market share provided in the report, are easily trusted due to their high level of accuracy and reliability. Readers are also provided with a study on current and future demand in the global Testosterone Replacement Therapy market.

The market estimation report consists of various market tools, such as:

>> Get Free Sample Report + All Related Graphs & Charts @ https://www.huddlemarketinsights.com/download-sample/92849

Leading Players and Testosterone Replacement Therapy Market Competition:

Are you looking for thorough analysis of the competition in the global Testosterone Replacement Therapy market? Well, this report offers just the right analysis you are looking for. Furthermore, you can ask for a customization of the report based on your requirements. The authors of the report are subject matter experts and hold strong knowledge and experience in market research. In the competitive analysis section, the report throws light on key strategies, future development plans, product portfolios, and other aspects of the business of top players. The report provides enough information and data to help readers to gain sound understanding of the vendor landscape.

This Report Focuses on the Global Top Players, Covered

AbbVie

Endo International

Eli lilly

Pfizer

Actavis (Allergan)

Bayer

Novartis

Teva

Mylan

Upsher-Smith

Ferring Pharmaceuticals

Kyowa Kirin

Acerus Pharmaceuticals

Product Type Segmentation:

Gels

Injections

Patches

Other

Market by Application Analysis

, market share and growth rate of Testosterone Replacement Therapy for each application, including

Hospitals

Clinics

Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Global Testosterone Replacement Therapy Market: Competitive Rivalry

The chapter on company profiles studies the various companies operating in the global Testosterone Replacement Therapy market. Evaluate the companys financial outlook, research and development status, and future expansion strategies. Analysts have also provided a detailed list of the strategic initiatives taken by the Testosterone Replacement Therapy market participants in the past few years to remain ahead of the competition.

A Detailed Study of Testosterone Replacement Therapy Market includes assessment of PORTERS Five Forces mechanism, PESTLE Analysis, Product Life Cycle Analysis, with Opportunity Orbits, and Opportunity Maps. These analysis techniques can assist you to establish the highest competitive forces to form your business and to work out company strategy. In this research study, we gathered, analyzed and interpreted information about Testosterone Replacement Therapy market, about a product and its services, about the past and present business targets. This Market research involves two types of data: Primary information which includes A group survey and The in-depth interviews, Secondary Research Information assembled by media sources, trade associations, government agencies, chambers of commerce, labor unions, and so on. Secondary research usually published in pamphlets, newsletters, trade publications, magazines, and newspapers.

Basic details were collected in a form of factual and numerical data, based on various market parameters, the data was analyzed from both demand and supply side of the market.

>> Any Questions? Fill Free To Enquire Here. Well Put You On The Right Path: https://www.huddlemarketinsights.com/inquiry/92849

Table of Content

Market Overview: This is the first section of the report that includes an overview of the scope of products offered in the global Testosterone Replacement Therapy market, segments by product and application, and market size.

Market Competition by Player: Here, the report shows how the competition in the global Testosterone Replacement Therapy market is growing or decreasing based on deep analysis of market concentrate rate, competitive situations Trends, expansions, mergers and acquisitions and other topics. It also shows how different companies are progressing in the global Testosterone Replacement Therapy market in terms of revenue, production, sales, and market share.

Company Profiles and Sales Data: This part of the report is very important as it gives statistical as well as other types of analysis of leading manufacturers in the global Testosterone Replacement Therapy market. Evaluate all players surveyed in the report by key business, gross margin, revenue, sales, price, competitors, manufacturing base, product specifications, product applications, and product categories.

Market by Product: This section carefully analyzes all product segments of the global Testosterone Replacement Therapy market.

Market by Application: Here, various application segments of the global Testosterone Replacement Therapy market are taken into account for the research study.

Market Forecast: It starts with revenue forecast and then continues with sales, sales growth rate, and revenue growth rate forecasts of the global Testosterone Replacement Therapy market. The forecasts are also provided taking into consideration product, application, and regional segments of the global Testosterone Replacement Therapy market.

Upstream Raw Materials: This section includes industrial chain analysis, manufacturing cost structure analysis, and key raw materials analysis of the global Testosterone Replacement Therapy market.

Marketing Strategy Analysis, Distributors: This study details the development trends of downstream customers, distributors, marketing channels, and the behavior and other factors of marketing channels such as indirect marketing and direct marketing.

Research Findings and Conclusion: This section is solely dedicated to the conclusion and findings of the research study on the global Testosterone Replacement Therapy market.

The report also includes dedicated sections on production and consumption analysis, key findings, important suggestions and recommendations, and other aspects. On the whole, it offers complete analysis and research study on the global Testosterone Replacement Therapy market to help players to ensure strong growth in the coming years.

To Know More Details Contact Us:

WilliamSales ManagerTelephone Number: +1 (601) 265 3434Website:www.huddlemarketinsights.comMail Id:inquiry@huddlemarketinsights.com

Read the original:
Testosterone Replacement Therapy Market Report 2019 Significant Trends and Factors Driving the Market Development Forecast to 2025 - Markets Gazette...

With having published myriads of reports for global clients, Persistence Market Research exhibits its expertise in the market research field. Our dedicated crew of professionals ride the wave of advanced technologies, such as artificial intelligence, and big data analytics, to project the adoption pattern and consumption trends regarding the market. A three-step quality check process data collection, triangulation, and validation is paramount while assuring the authenticity of the information captured.

Global Cosmetic Peptide Synthesis Market Report

The latest business intelligence study by PMR suggests that the global market size of Cosmetic Peptide Synthesis reached US$ xx Mn/Bn in 2018 and is anticipated to register US$ xx Mn/Bn by the end of forecast period with a CAGR of xx%. The research study focuses on the drivers, restraints, opportunities and trends impacting the Cosmetic Peptide Synthesis Market.

All the relevant vendors running in the Cosmetic Peptide Synthesis Market are examined based on market share and product footprint.

Get Sample Copy of this Report at https://www.persistencemarketresearch.com/samples/26248?source=atm

What does the Cosmetic Peptide Synthesis Market research hold for the readers?

Speak To Research Analyst For Detailed Insights athttps://www.persistencemarketresearch.com/ask-an-expert/26248?source=atm

The Cosmetic Peptide Synthesis Market research clears away the following queries:

And many more

Key players in the cosmetic peptide synthesis market are focused on commercializing cosmetic peptide synthesis at a large scale at a very economical price across the globe. Cosmetic peptides are generally small molecule collagen that contains about 2 to 10 amino acid groups. The bioactive cosmetic peptides synthesized are capable of entering the dermis via interstitial spaces in order to function efficiently, thereby promoting the collagen proliferation and hyaluronic acid that leads to skin thickness and wrinkles reduction. A number of new entrants in the global cosmetic peptide synthesis market are entering into collaborations and agreements with the already existing cosmetic peptide synthesis players in order to expand their product reach and strengthen their business portfolio.

Customized cosmetic peptide synthesis service lately has entered into the cosmetic industry. The growing demand and availability of commercialized cosmetic peptide from CROs/CMOs, pharmaceutical and biotech industries and research & development centers is projected to propel cosmetic peptide synthesis market growth over the coming years. The cosmetic peptide synthesis market is categorized on the basis of product type, application, technology, and end user. On the basis of product type, the cosmetic peptide synthesis market is classified into signal peptides, neurotransmitter-inhibiting peptides, carrier peptides, antioxidant and anti-inflammatory peptides, and enzyme inhibitor peptides. Also, the cosmetic peptide synthesis finds large applications in the anti-aging, eye care, anti-pigmentation and hair growth segment in the cosmetic peptide synthesis market.

Ease in cosmetic peptides synthesis in large quantities of mg to kg at exceptionally economical prices is anticipated to fuel the growth of cosmetic peptide synthesis market across the globe. The introduction of highly efficient scale-up technologies with the capability of cost-effective bulk synthesis of cosmetic peptide along with ready availability of additional cosmetic peptide modifications from manufacturers is projected to drive revenue generation in global cosmetic peptide synthesis market. Also, synthesis of the high-quality product by the key players with high reproducibility in order to cater the increasing demand for economical cosmetic peptide synthesis services is another major factor that further drives the revenue generation in cosmetic peptide synthesis market. The growing demand for cosmetic peptide in the life science research and pharmaceutical sector for drug development activities enables the cosmetic peptide synthesis market to grow at a significant growth rate.

The global cosmetic peptide synthesis market is segmented on basis of product type, technology, application, end user and geographic region:

On the basis of product type, signal peptides followed by neurotransmitter-inhibiting peptides registered significant revenue share in cosmetic peptide synthesis market. Owing to their natural occurrence, the capability to stimulate distinct cellular functions and high-stability, signal peptides segment generates the highest revenues in global cosmetic peptide synthesis market. This segment is further anticipated to dominate the cosmetic peptide synthesis market over the forecast period. On the basis of application, anti-aging and hair growth segments are expected to record significant use of cosmetic peptides in the cosmetic peptide synthesis market as cosmetic peptides act as attractive key ingredients in the cosmeceutical products. However, pharmaceutical and biotech companies followed by contract manufacturing organizations among end users are anticipated to mark the highest revenue growth rate over the forecast period by 2026.

Based on geography, the global cosmetic peptide synthesis market is segmented into six key regions viz. North America, Latin America, Europe, Asia Pacific Excluding China, China, and the Middle East & Africa. Among the six key regions studied in cosmetic peptide synthesis market, North America accounted for the largest revenue shares in global cosmetic peptide synthesis market owing to the presence of large-scale pharmaceutical and biotech industries. North America cosmetic peptide synthesis market is followed by Europe and Asia-Pacific in terms of market value. However, in the Middle East and Africa region cosmetic peptide synthesis market does not register a significant revenue generation due to limited demand from contract manufacturing organizations and comparative fewer R&D investments in the region. North America is projected to continue its dominance in cosmetic peptide synthesis market over the forecast period owing to increasing investments for development of custom cosmetic peptides in the region.

Some of the market players featured in global cosmetic peptide synthesis market report include GenScript, Creative Peptides, Peptides International, RS Synthesis, LLC., Bio Basic Inc., AAPPTec., even AG, Activotec and others. The key players mentioned in the global cosmetic peptide synthesis market focus majorly on product development strategies and carry out various mergers and acquisitions in order to expand their product reach.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

Get Access To Research Methodology Prepared By Experts athttps://www.persistencemarketresearch.com/methodology/26248?source=atm

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

305 Broadway, 7th FloorNew York City, NY 10007United StatesPh.no. +1-646-568-7751E-mail id- [emailprotected]Website: http://www.persistencemarketresearch.com

See the original post here:
Global Testosterone Replacement Therapy Market Report 2019 Analysis, Growth, Size, Share, Trends and Forecast 2019 2025 - Health News Office

After its stock gained a third of its value over the past 60 days, AbbVie, Inc. (NYSE:ABBV) beat revenue and earnings expectations and obtained potential fuel that may allow it to extend its current share price uptrend.

The companys share price exhibited steady growth and more than doubled from its initial public opening (IPO) price of $34.40 to more than $75 by August 2017. After a brief spike to nearly $125 over the next five months, the share price reversed direction and gave back those quick gains by the beginning of 2019.

However, the chart below illustrates that the share price was still at its long-term uptrend in January 2019. However, after dropping further, the share price has been rising steadily since mid-August 2019 and the positive results from the current quarterly report should continue to power the current share price recovery.

Released on November 1, AbbVies report for the third quarter of 2019 which ended on September 30, 2019 revealed a 3% increase in worldwide net revenues to $8.48 billion. Diluted earnings per share (EPS) were $1.26. The adjusted EPS of $2.33 was nearly 9% above the $2.14 adjusted EPS from the same period last year and beat analysts earnings expectations of $2.29 by 1.75%. After missing earnings estimates by 2% in the last quarter of 2018, AbbVie managed to beat earnings expectations in the last three consecutive quarters and four times in the last five periods.

The companys current $1.07 quarterly dividend is 11.5% higher than the companys $0.96 payout from the same quarter last year. This new quarterly payout corresponds to a $4.28 annualized distribution. Using the $79.55 share price as of closing on October 31, 2019, the current payout is equivalent to a 5.38% forward dividend yield. This is 32.5% above the companys own 4.06% yield average over the past five years.

Additionally, AbbVies current yield level is the highest among the companys peers in the Major Drug Manufacturers market segment. Furthermore, AbbVies current yield is at least 20% higher than the segments only other yields in excess of 4% Takeda Pharmaceutical Co Ltd (NYSE:TAK) at 4.51% and GlaxoSmithKline Plc (NYSE:GSK) at 4.37%. As the segments top value, AbbVies current yield is nearly triple the segments 1.8% simple average, as well as nearly double the 2.8% average yield of the segments only dividend paying companies. Furthermore, in a sector that is renowned for its low dividend payouts, AbbVies current yield is nearly 10-fold higher than the 0.52% simple yield average of the entire Health Care sector.

As a separate legal entity, AbbVies current streak of consecutive annual dividend hikes only goes back six years. However, the companys history of dividend payouts as part of Abbot Labs goes back several decades. In 2013 the year of the divestiture from Abbott Laboratories the two companies paid individual dividends. However, the sum of the two payouts was higher than Abbott Laboratories total dividend payout over the previous year. Furthermore, both companies have continued to hike their respective annual dividends every year since 2013.

Therefore, we can give credit for the past dividend hikes to both companies and consider the annual dividend hikes since 2012 to be a continuation of the previous streak. Under that assumption, AbbVie has boosted its annual dividend payout for the past 46 consecutive years. Since AbbVie is a component of the S&P 500 Index and meets all the other market capitalization, liquidity and trading volume requirements, we can include the company as a part of the S&P 500 Dividend Aristocrats group.

Even disregarding the dividend distributions that were delivered prior to 2013, AbbVie has enhanced its annual dividend distribution amount by nearly 170% just over the past six years that it has been its own business entity. That level of advancement corresponds to an average growth rate of nearly 18% per year.

The share price entered the trailing 12-month period by riding the downtrend that began in January 2018. After passing through its 52-week low of $94.27 on November 30, 2018, the share price declined by nearly 50% before reaching the 52-week low of $62.98 on August 15, 2019.

However, since reversing its trend in mid-August, the share price has recovered more than half of its losses since the November peak and closed on October 31, 2019, at $79.55. This was flat with the price level of one year ago and 26% higher than the 52-week low from August. Furthermore, the share price surged 3.5% on positive financial results in just the first hour of trading on Nov. 1. The share price trailed off a little afterwards even though it held on to a 2.5% gain as of noon on the same day.

With the share price at last years levels, dividend income payouts have contributed all of the total gains of approximately 5% over the trailing 12 months. However, capital gains have contributed most of the total gains of more than 60% over the past three years.

Headquartered in North Chicago, Illinois, and founded when Abbott Labs (NYSE:ABT) divested its proprietary pharmaceutical business in 2013, AbbVie Inc. discovers, develops, manufactures and sells pharmaceutical products. The most prominent pharmaceutical brands in the companys current portfolio are HUMIRA for the treatment of autoimmune diseases, IMBRUVICA for the treatment of patients with chronic lymphocytic leukemia and VIEKIRA PAK for the treatment of adults with hepatitis C. Additionally, AbbVie offers pharmaceutical treatments for HIV, hypothyroidism, prostate cancer, endometriosis, anemia, Parkinsons disease and multiple sclerosis, as well as treatments for testosterone replacement therapy and pancreatic enzyme therapy for exocrine pancreatic insufficiency.

Ned Piplovicis the assistant editor of website content at Eagle Financial Publications. He graduated from Columbia University with a Bachelors degree in Economics and Philosophy. Prior to joining Eagle, Ned spent 15 years in corporate operations and financial management. Ned writes forwww.DividendInvestor.comandwww.StockInvestor.com.

Read more from the original source:
After Gaining 33% in 60 Days, AbbVie Beats Third-Quarter Earnings Expectations (NYSE:ABBV) - Stock Investor

A new market research report on theGlobal Artificial Intelligence Chip markethas introduced byKD Market Insights. The report is dedicated to in-depth industry analysis of the globalArtificial Intelligence Chipmarket. TheGlobal Artificial Intelligence Chipanalysis is broken down on different segmentation levelsincluding MarketBy Chip Type,By Application,By Technology, By Processing Type, By Industry Vertical.

Artificial intelligence (AI) has been the most progressive technology since its introduction in the 1950s. It is associated with human intelligence with characteristics such as language understanding, reasoning, learning, problem-solving, and others. Manufacturers in the market witness enormous underlying intellectual challenges in the development and revision of such technology. It is positioned as the core of the next-generation software technologies in the market.

Get Report Sample Copy @https://www.kdmarketinsights.com/sample/3434The factors that drive the growth of the global artificial intelligence chip market include increase in demand for smart homes, development of smart cities, and emergence of quantum computing. However, lack of skilled workforce restrains the market growth. Further, in the near future, increased adoption of AI chips in the developing regions and development of smarter robots are expected to provide lucrative opportunities for the key players operating in the global artificial intelligence chip market.

The globalartificial intelligence chip marketis segmented based on chip type, application, industry vertical, technology, and geography. By chip type, the market is categorized into GPU, ASIC, FPGA, CPU, and others. Based on application, it is divided into machine learning, natural language processing (NLP), robotic process automation, speech recognition, and others. On the basis of technology, the market is segmented into system-on-chip, system-in-package, multi-chip module, and others. Based on processing type, it is bifurcated into edge and cloud. The industry verticals considered in the study include media & advertising, BFSI, IT & telecom, retail, healthcare, automotive & transportation, and others.

Geographically, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.The key players profiled in the report include AMD (Advanced Micro Devices), Google, Inc., Intel Corporation, NVIDIA, Baidu, Graphcore, Qualcomm, Adapteva, UC-Davis, Mythic, and others.

Key Benefits for Artificial Intelligence Chip Market: This study comprises analytical depiction of the global artificial intelligence chip market along with the current trends and future estimations to depict the imminent investment pockets. The overall market potential is determined to understand the profitable trends to gain a stronger coverage in the market. The report presents information related to key drivers, restraints, and opportunities with a detailed impact analysis. The current market is quantitatively analyzed from 2017 to 2025 to highlight the financial competency of the market. Porters five forces analysis illustrates the potency of the buyers and suppliers.

Artificial Intelligence Chip Key Market Segments:

By Chip Type GPU ASIC FPGA CPU Others

By Application Machine Learning Deep Learning (Image Recognition, Computer Vision) Predictive Analysis Others Natural Language Processing (NLP) Translation Classification & Clustering Information Extraction Robotic Process Automation Speech Recognition Speech to Text Text to Speech Others (Expert Systems, Planning, and Scheduling)

By Technology System-on-Chip (SoC) System-in-Package (SIP) Multi-chip Module Others

By Processing Type Edge Cloud

By Industry Vertical Media & Advertising BFSI IT & Telecom Retail Healthcare Automotive & Transportation Others

By RegionNorth America U.S. Canada MexicoEurope UK Germany France Russia Rest of EuropeAsia-Pacific China Japan India Australia Rest of Asia-PacificLAMEA Latin America Middle East Africa

Key Market Players Profiled AMD (Advanced Micro Devices) Google, Inc. Intel Corporation NVIDIA Baidu Graphcore Qualcomm Adapteva UC-Davis Mythic Others

Access Complete Research Report with TOC @https://www.kdmarketinsights.com/product/artificial-intelligence-chip-market-amr

Table of Content

CHAPTER 1: INTRODUCTION1.1. REPORT DESCRIPTION1.2. KEY BENEFITS FOR STAKEHOLDERS1.3. KEY MARKET SEGMENTS1.4. RESEARCH METHODOLOGY1.4.1. Primary research1.4.2. Secondary research1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY2.1. INDUSTRY ROADMAP2.2. CXO PERSPECTIVE

CHAPTER 3: MARKET OVERVIEW3.1. MARKET DEFINITION AND SCOPE3.2. KEY FINDINGS3.2.1. Top impacting factors3.2.2. Top investment pockets3.2.3. Top winning strategies3.3. PORTERS FIVE FORCES ANALYSIS3.4. MARKET SHARE ANALYSIS, 2017 (%)3.5. MARKET DYNAMICS3.5.1. Drivers3.5.1.1. Increase in demand for smart homes & smart cities3.5.1.2. Rise in investments in AI startups3.5.1.3. Emergence of quantum computing3.5.2. Restraint3.5.2.1. Dearth of skilled workforce3.5.3. Opportunities3.5.3.1. Increased adoption of AI chips in the developing regions3.5.3.2. Development of smarter robots

CHAPTER 4: ARTIFICIAL INTELLIGENCE CHIP MARKET, BY CHIP TYPE4.1. OVERVIEW4.2. GPU4.2.1. Key market trends, growth factors and opportunities4.2.2. Market size and forecast, by region4.2.3. Market analysis by country4.3. ASIC4.3.1. Key market trends, growth factors, and opportunities4.3.2. Market size and forecast, by region4.3.3. Market analysis by country4.4. FPGA4.4.1. Key market trends, growth factors, and opportunities4.4.2. Market size and forecast, by region4.4.3. Market analysis by country4.5. CPU4.5.1. Key market trends, growth factors, and opportunities4.5.2. Market size and forecast, by region4.5.3. Market analysis by country4.6. OTHERS (NPU & HYBRID CHIP)4.6.1. Key market trends, growth factors, and opportunities4.6.2. Market size and forecast, by region4.6.3. Market analysis by country

CHAPTER 5: ARTIFICIAL INTELLIGENCE CHIP MARKET, BY APPLICATION5.1. OVERVIEW5.2. MACHINE LEARNING5.2.1. Key market trends, growth factors and opportunities5.2.2. Market size and forecast, by region5.2.3. Deep learning (Image recognition, Computer vision)5.2.4. Predictive analysis5.2.5. Others (Decision tree learning, Inductive logic programming, Reinforcement learning, and others)5.2.6. Market analysis by country5.3. NATURAL LANGUAGE PROCESSING (NLP)5.3.1. Key market trends, growth factors, and opportunities5.3.2. Market size and forecast, by region5.3.3. Translation5.3.4. Classification & clustering5.3.5. Information extraction5.3.6. Market analysis by country5.4. ROBOTIC PROCESS AUTOMATION5.4.1. Key market trends, growth factors, and opportunities5.4.2. Market size and forecast, by region5.4.3. Market analysis by country5.5. SPEECH RECOGNITION5.5.1. Key market trends, growth factors, and opportunities5.5.2. Market size and forecast, by region5.5.3. Speech to text5.5.4. Text to speech5.5.5. Market analysis by country5.6. OTHERS5.6.1. Key market trends, growth factors, and opportunities5.6.2. Market size and forecast, by region5.6.3. Market analysis by country

CHAPTER 6: ARTIFICIAL INTELLIGENCE CHIP MARKET, BY TECHNOLOGY6.1. OVERVIEW6.2. SYSTEM-ON-CHIP (SOC)6.2.1. Key market trends, growth factors and opportunities6.2.2. Market size and forecast, by region6.2.3. Market analysis by country6.3. SYSTEM-IN-PACKAGE (SIP)6.3.1. Key market trends, growth factors, and opportunities6.3.2. Market size and forecast, by region6.3.3. Market analysis by country6.4. MULTI-CHIP MODULE6.4.1. Key market trends, growth factors, and opportunities6.4.2. Market size and forecast, by region6.4.3. Market analysis by country6.5. OTHERS (PACKAGE IN PACKAGE, TSV)6.5.1. Key market trends, growth factors, and opportunities6.5.2. Market size and forecast, by region6.5.3. Market analysis by country

CHAPTER 7: ARTIFICIAL INTELLIGENCE CHIP MARKET, BY PROCESSING TYPE7.1. OVERVIEW7.2. EDGE7.2.1. Key market trends, growth factors and opportunities7.2.2. Market size and forecast, by region7.2.3. Market analysis by country7.3. CLOUD7.3.1. Key market trends, growth factors, and opportunities7.3.2. Market size and forecast, by region7.3.3. Market analysis by country

CHAPTER 8: ARTIFICIAL INTELLIGENCE CHIP MARKET, BY INDUSTRY VERTICAL8.1. OVERVIEW8.2. MEDIA & ADVERTISING8.2.1. Key market trends, growth factors and opportunities8.2.2. Market size and forecast, by region8.2.3. Market analysis by country8.2.4. Market size and forecast, by processing type8.3. BFSI8.3.1. Key market trends, growth factors and opportunities8.3.2. Market size and forecast, by region8.3.3. Market analysis by country8.3.4. Market size and forecast, by processing type8.4. IT & TELECOM8.4.1. Key market trends, growth factors and opportunities8.4.2. Market size and forecast, by region8.4.3. Market analysis by country8.4.4. Market size and forecast, by processing type8.5. RETAIL8.5.1. Key market trends, growth factors and opportunities8.5.2. Market size and forecast, by region8.5.3. Market analysis by country8.5.4. Market size and forecast, by processing type8.6. HEALTHCARE8.6.1. Key market trends, growth factors and opportunities8.6.2. Market size and forecast, by region8.6.3. Market analysis by country8.6.4. Market size and forecast, by processing type8.7. AUTOMOTIVE8.7.1. Key market trends, growth factors and opportunities8.7.2. Market size and forecast, by region8.7.3. Market analysis by country8.7.4. Market size and forecast, by processing type8.8. OTHERS8.8.1. Key market trends, growth factors and opportunities8.8.2. Market size and forecast, by region8.8.3. Market analysis by country8.8.4. Market size and forecast, by processing type

CHAPTER 9: ARTIFICIAL INTELLIGENCE CHIP MARKET, BY REGION9.1. OVERVIEW9.2. NORTH AMERICA9.2.1. Key market trends, growth factors, and opportunities9.2.2. Market size and forecast, by chip type9.2.3. Market size and forecast, by application9.2.4. Market size and forecast, by technology9.2.5. Market size and forecast, by processing type9.2.6. Market size and forecast, by industry vertical9.2.7. Market analysis by country9.2.7.1. U.S.9.2.7.1.1. Market size and forecast, by chip type9.2.7.1.2. Market size and forecast, by application9.2.7.1.3. Market size and forecast, by technology9.2.7.1.4. Market size and forecast, by processing type9.2.7.1.5. Market size and forecast, by industry vertical9.2.7.2. Canada9.2.7.2.1. Market size and forecast, by chip type9.2.7.2.2. Market size and forecast, by application9.2.7.2.3. Market size and forecast, by technology9.2.7.2.4. Market size and forecast, by processing type9.2.7.2.5. Market size and forecast, by industry vertical9.2.7.3. Mexico9.2.7.3.1. Market size and forecast, by chip type9.2.7.3.2. Market size and forecast, by application9.2.7.3.3. Market size and forecast, by technology9.2.7.3.4. Market size and forecast, by processing type9.2.7.3.5. Market size and forecast, by industry vertical

9.3. EUROPE9.3.1. Key market trends, growth factors, and opportunities9.3.2. Market size and forecast, by chip type9.3.3. Market size and forecast, by application9.3.4. Market size and forecast, by technology9.3.5. Market size and forecast, by processing type9.3.6. Market size and forecast, by industry vertical9.3.7. Market analysis by country9.3.7.1. U.K.9.3.7.1.1. Market size and forecast, by chip type9.3.7.1.2. Market size and forecast, by application9.3.7.1.3. Market size and forecast, by technology9.3.7.1.4. Market size and forecast, by processing type9.3.7.1.5. Market size and forecast, by industry vertical9.3.7.2. Germany9.3.7.2.1. Market size and forecast, by chip type9.3.7.2.2. Market size and forecast, by application9.3.7.2.3. Market size and forecast, by technology9.3.7.2.4. Market size and forecast, by processing type9.3.7.2.5. Market size and forecast, by industry vertical9.3.7.3. France9.3.7.3.1. Market size and forecast, by chip type9.3.7.3.2. Market size and forecast, by application9.3.7.3.3. Market size and forecast, by technology9.3.7.3.4. Market size and forecast, by processing type9.3.7.3.5. Market size and forecast, by industry vertical9.3.7.4. Russia9.3.7.4.1. Market size and forecast, by chip type9.3.7.4.2. Market size and forecast, by application9.3.7.4.3. Market size and forecast, by technology9.3.7.4.4. Market size and forecast, by processing type9.3.7.4.5. Market size and forecast, by industry vertical

Continue @Check for Discount @https://www.kdmarketinsights.com/discount/3434About Us:KD Market Insightsoffers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market.Contact Us:KD Market Insights150 State Street, Albany,New York, USA 12207+1 (518) 300-1215Email:[emailprotected]Website:www.kdmarketinsights.comhttps://prnewslight.blogspot.com/https://newstrendmirror.blogspot.com/

Read this article:
Testosterone Replacement Therapy Market: Business Growth, Development Factors, Applications, and Future Prospects - Health News Office

This is therefore a contrasting of the institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation in HEXO Corp. (NYSE:HEXO) and Lipocine Inc. (NASDAQ:LPCN). The two are both Drugs Generic companies that compete with one another.

Valuation and Earnings

Demonstrates HEXO Corp. and Lipocine Inc. earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 shows us HEXO Corp. and Lipocine Inc.s return on equity, return on assets and net margins.

Analyst Ratings

The Ratings and Recommendations for HEXO Corp. and Lipocine Inc. are featured in the next table.

HEXO Corp.s average price target is $4, while its potential upside is 82.65%.

Insider & Institutional Ownership

Roughly 9.15% of HEXO Corp. shares are owned by institutional investors while 13.4% of Lipocine Inc. are owned by institutional investors. Insiders owned 8.04% of HEXO Corp. shares. Insiders Competitively, owned 3.4% of Lipocine Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year HEXO Corp. has weaker performance than Lipocine Inc.

Summary

HEXO Corp. beats on 8 of the 10 factors Lipocine Inc.

Lipocine Inc., a specialty pharmaceutical company, develops pharmaceutical products using its oral drug delivery technology in the areas of mens and womens health. The company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is LPCN 1021, an oral testosterone replacement therapy designed for twice-a-day dosing that has completed Phase 3 testing. The companys pipeline candidates also include LPCN 1111, a next generation oral testosterone therapy product with once daily dosing that is in Phase 2 testing; and LPCN 1107, which has completed Phase 2 testing for the prevention of recurrent preterm birth. Lipocine Inc. is headquartered in Salt Lake City, Utah.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read the rest here:
Contrasting of HEXO Corp. (HEXO) and Lipocine Inc. (NASDAQ:LPCN) - MS Wkly

After some huge US approvals in recent months, November is shaping up to be quieter. There are no decisions on future blockbusters set for next month, Vantages regular PDUFA analysis shows.

However, some of the upcoming verdicts will still be a big deal for the companies involved. This includes Agile Therapeutics and Lipocine, which hope to bounce back from complete response letters for the Twirla contraceptive patch and the testosterone replacement therapy Tlando respectively.

Twirla's chances of getting approved got a boost yesterday, with an FDA advisory committee voting 14-1 that the benefits of the projects outweigh its risks an unexpected outcome given scathing briefing documentsreleased on Monday. The agency questioned the patch's efficacy, thoughAgile put unimpressive results from the pivotal Secure trial down to a high number of obese participants, in whom contraceptives do not work as well.

The FDA questioned Twirla's efficacy even in non-obese women, however, and also raised doubts about whether the project is a low-dose, and therefore potentially safercontraceptive, as Agile has claimed. Shares in the company recovered today after slumping on the briefing docs, but investors' wild ride might not be over yet.

Meanwhile, Lipocine will hope that an ambulatory blood pressure study will answer questions raised in the FDAs May 2018 CRL. The company believes that Tlando, an oral therapy, will have an edge over injectable testosterone products. Another oral contender got the FDA nod earlier this year, Clarus Therapeutics Jatenzo, andLipocine is embroiled in a legal wrangle with Clarus over intellectual property.

A project that should get a smoother ride is Shionogis S-649266, or cefiderocol, a novel antibiotic targeting Gram-negative pathogens. The project recently got an adcom thumbs up, with panellists voting14-2 in favour ofapproval for patients with complicated urinary tract infections and limited or no alternative treatment options.

The project has also shown promise in pneumonia. Still, as with many antibiotics, especially those saved for drug-resistant infections, succeeding commercially will be trickier.

Meanwhile, Redhill Biopharmas Talicia, which combines two antibiotics and a proton pump inhibitor, is awaiting a verdict in Helicobacter pylori infection. It has a good shot after a positive result in the Eradicate Hp2 trial, and a recent tie-up with Cosmo Pharmaceuticals should also give Redhill sufficient funds for launch.

However, sales expectations are not huge, with EvaluatePharma consensus predicting $27m in 2024.

Supplements

As for potential supplementary approvals, Lilly and Boehringer hope to get cardiovascular data on the label of their DPPIV inhibitor Tradjenta. However, the product has only shown noninferiority to placebo in the Carmelina study; with other diabetes drugs like the SGLT2s and GLP1s showing cardioprotective effects, the DPPIV class has been put in the shade.

Other decisions, including a verdict on Pfizers Humira biosimilar, continue to be expected sometime in the fourth quarter.

The biggest regulatory event of November is not an approval but rather an advisory committee meeting, for Amarins Vascepa. On November 14 panellists will consider the products expanded use for the reduction of cardiovascular events in patients with high triglycerides; the FDA had previously been expected to make a call here in September.

EvaluatePharma consensus forecasts 2024 Vascepa sales of $2.2bn, but Leerink analysts believe that, if the drug does get expanded approval, US revenues could exceed $4bn.

The rest is here:
Go or no go? Agile and Lipocine hope to make it third time lucky - Vantage